Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Koji Haratani(Dana-Farber Cancer Institute), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Kimio Yonesaka(Kindai University), Hiroyasu Kaneda(Osaka City University), Masayuki Takeda(Kindai University), Ryoji Kato(Kindai University), Kaoru Tanaka(Kindai University), Keita Kudo(Osaka Minami Medical Center), Yasutaka Chiba(Kindai University Hospital), Yoshikazu Hasegawa(Izumi City General Hospital), Hidetoshi Hayashi(Kindai University)
Cited by 1,006
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k